To reach the next value inflection
LicenseRx asset brief
Transgenic Mouse Model Expressing C217G Uromodulin
Probability of Success
26% · grade B · Medium data confidence
Model PoS 26% (grade B, medium data confidence). Strongest signals: Data maturity, Modality feasibility. Biggest drag: IP position.
Data maturity (22%)
59
Preclinical; human data.
IP position (16%)
45
No clear patent status in public data -- treat IP as unpriced until counsel confirms.
Modality feasibility (14%)
80
Diagnostic/biomarker -- can monetize via service before full approval.
Indication pull (14%)
74
Cardiometabolic -- active buyer appetite.
Competitive whitespace (12%)
80
Under-served segment.
Translational evidence (12%)
62
Public evidence mentions: human, mouse.
Licensing readiness (10%)
94
Listed as available for licensing; established tech-transfer office; 1 public source link(s).
Unlock the full strategic deep dive
Cost to the next milestone, decisive data, relevant articles, and the partner-ready development plan for this asset.
View Operator access See what's included →